how many people are on glp 1 Rate of cases involving GLP-1 receptor agonists per one million US GLP-1 use peaks in middle
Description
Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
To improve the local map quality, each refined particle was subjected into another 3D classification with a loose mask of ECD in RELION
Nothing here is medical advice
One possibility is that GLP-1R endocytosis is required for agonist uptake by the brain via hypothalamic tanycytes, as described for leptin 65
